Skip to main content

Table 3 Characteristics of patients who were or were not referred to cardiology

From: Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

  Cardiology referral (n = 75) No referral (n = 39) P value
Year of diagnosis    0.076
 2010 11 (15%) 9 (23%)  
 2011 24 (32%) 15 (38%)  
 2012 24 (32%) 11 (28%)  
 2013 16 (21%) 4 (10%)  
Location    0.041
 4o care centre 20 (26%) 4 (10%)  
 Peripheral centre 55 (73%) 35 (90%)  
Age at diagnosis (y) 57 ± 10 56 ± 12 0.714
T    0.877
 0 1 (1%) 0  
 1 27 (37%) 14 (36%)  
 2 33 (45%) 20 (51%)  
 3 3 (4%) 2 (5%)  
 4 10 (14%) 3 (8%)  
N    0.143
 0 40 (54%) 13 (34%)  
 1 24 (32%) 19 (50%)  
 2 6 (8%) 2 (5%)  
 3 4 (5%) 4 (11%)  
Mastectomy 58 (77%) 38 (97%) 0.005
Radiation 58 (77%) 29 (74%) 0.723
Radiation dose (Gy) 55 (42.5,90) 80 (0,92.5) 0.667
Anthracycline dose (mg/m2) 240 (150,240) 240 (150,240) 0.298
Pre-existing CVD 4 (5%) 2 (5%) 0.963
CV risk factors 39 (52%) 18 (46%) 0.554
Baseline LVEF 61% ±6 60% ±7 0.435
LVEF at time of deterioration 45% (42,47) 47% (45,48) 0.003
Symptoms of HF 24 (32%) 3 (8%) 0.004
  1. Values shown are counts (percentages), mean ± SD, or median (Q1, Q3). Abbreviations: CV Cardiovascular, CVD Cardiovascular disease, HF Heart failure, LVEF Left ventricular ejection fraction, N Nodal stage, T Tumour stage